RecruitingPhase 1Phase 2NCT04219254

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Sponsor

BioInvent International AB

Enrollment

197 participants

Start Date

Jun 29, 2020

Study Type

INTERVENTIONAL

Conditions

Solid Tumor, Adult

Summary

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BI1206 for people with solid tumor, adult. The study is currently recruiting participants at 26 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBI1206

BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa. The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase

Locations(26)

University of California Los Angeles

Los Angeles, California, United States

Sarah Cannon Research Institute

Denver, Colorado, United States

HealthPartners Institute - Regions Cancer Care Center,

Saint Paul, Minnesota, United States

Oklahoma University , Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

NEXT Oncology

San Antonio, Texas, United States

LTD High Technology Hospital Med Center

Batumi, Georgia

Israel-Georgian Medical Research Clinic Helsicore

Tbilisi, Georgia

Jerarsi Clinic

Tbilisi, Georgia

Medizinische Hochschule Hannover

Hanover, Germany

Nationales Centrum für Tumorerkrankungen

Heidelberg, Germany

Universität des Saarlandes

Homburg, Germany

Maria Skłodowska-Curie National Institute of Oncology

Gliwice, Poland

Medical University of Silesia

Katowice, Poland

Instytut Centrum Zdrowia Matki Polki

Lodz, Poland

Institutul Oncologic "Prof. Dr. Ion Chiricuta"

Cluj-Napoca, Romania

Centrul de Oncologie SF Nectarie SRL

Craiova, Romania

Hospital Universitari Dexeus

Barcelona, Spain

Hospital Universitari Vall D´Hebron

Barcelona, Spain

Institut Català d'Oncologia Hospital Duran i Reynals

Barcelona, Spain

Hospital Puerta de Hierro

Majadahonda, Spain

Hm Ciocc Málaga

Málaga, Spain

Clinica Universidad de Navarra

Pamplona, Spain

Hospital Virgen de la Macarena

Seville, Spain

Sahlgrenska University Hospital

Gothenburg, Sweden

Lund University Hospital

Lund, Sweden

Karolinska University Hospital, Solna

Stockholm, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04219254

Related Trials

Advanced or Recurrent Solid Tumors Treated With SHetA2

NCT049285081 location

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT0691575316 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

First In Human Study of CX-2051 in Advanced Solid Tumors

NCT062656888 locations

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

NCT068243631 location